Hannah Bowrey, PhD

Esketamine Nasal Spray Improves Functioning in Patients with Treatment Resistant Depression: Results from ESCAPE‑TRD

This analysis evaluated changes in functioning and productivity in patients with treatment resistant depression who received either esketamine nasal spray or quetiapine extended release, ...

Hannah Bowrey , PhD;

10/26/2023

Real-World Safety Profile of Esketamine Nasal Spray During the First 12 Treatment Sessions: An Analysis at 46 Months After Approval in the United States

This research examined real-world safety data for esketamine nasal spray (ESK) for the first 46 months after product approval, with a focus on adverse events (AEs) of interest (i.e., seda...

Hannah Bowrey , PhD;

10/26/2023

Time Dynamics of Adverse Events of Interest Occurring with Esketamine Nasal Spray and Quetiapine Extended Release: Results from the ESCAPE‑TRD Phase IIIb Trial

This safety analysis evaluated the duration of treatment-emergent adverse events (TEAEs) reported for esketamine nasal spray (ESK-NS) versus quetiapine extended release (QTP-XR) in patien...

Hannah Bowrey , PhD;

10/26/2023